The early bird rate for our next event D4 (Data-Driven Drug Development) Europe expires this Friday, the only event where attendees will receive data, evidence and case studies from the world’s leading minds in pharma. This meeting is designed specifically to cater for senior people in pharma, combining strategic insights of value to IT/R&D leaders, […]
Scientists have successfully grown a ‘cyber organoid,’ a simplified organ formed from stem cells with integrated electrochemical sensors to observe its development. Organs are formed by the self-assembly of stem cells into complex 3D structures. However, due to the difficulty of monitoring this process there are still significant gaps in scientists’ understanding. Electrochemical sensors have […]
Scientists have developed minimally invasive brain probes that can selectively deliver drugs in-vivo and stimulate cells with light. The probes can be wirelessly controlled from a smartphone. It is hoped that the probes will advance understanding of neurodegenerative disease by allowing the manipulation of brain circuits. Delivering drug infusions into the brain has previously been […]
In any field, data science is an emerging area where roles can be hard to define or quantify by hiring managers. For those looking to employ data scientists within their business, this role can lead to a wealth of unanswered questions. This chapter from our Data Solutions for Drug Development Report, sets out key tips […]
The Digital DNA series explores the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. As part of the Digital DNA series we talked to Kevin Quinn, Chief Product Officer at Nebula Genomics. He […]
The Digital DNA series will explore the role of large-scale genetic testing in science, industry and society. We aim to understand both the benefits and risks of this emerging technology and see what the future may hold. In the first of our Digital DNA series, we talked to Dr. Peter Ney, a researcher in the […]
Epitranscriptomics – An Interview with Samie Jaffrey, Professor of Pharmacology, Weill Cornell Medicine
The study of epitranscriptomics has ramifications for better understanding disease symptoms and pushing forward drug treatment. But it’s also an emerging area still misunderstood by many. FLG spoke to Dr Samie Jaffrey, Professor of Pharmacology, Weill Cornell Medicine, about the field.
Researchers have found a weakness in software used for genomics data storage, which could leave patients’ information vulnerable to cyber-attacks. The increasing speed and availability of genetic sequencing technologies has enabled personalised medicine to make significant progress over the last few years. Patient’s genetic profiles are considered when choosing chemotherapy treatment and cures are being […]
NASH is present in nine to 18 million people in America alone. Yet no single drug has yet been approved for its treatment. To discuss why therapies are proving so elusive, and where efforts will be made in the future, FLG has gathered some of the most influential names in the field to discuss the problem in our latest webinar: New Approaches to the Old Hunt for NASH Therapies, held at 4pm on 11 July 2019.
Biobank 2019 – An Interview with Anthony Whetton, Professor of Cancer Cell Biology, University of Manchester
The UK Biobank’s 2019 scientific conference concluded this month. We talked to speaker Anthony Whetton, Professor of Cancer Cell Biology at the University of Manchester and Director of the Stoller Biomarker Discovery Centre, about large-scale multi-omic data within UK Biobank.
Inscripta has presented its scalable platform for benchtop digital CRISPR engineering, described as world first, at the 2019 Synthetic Biology: Engineering, Evolution & Design (SEED) conference. The technology, “CRISPR-enabled trackable genome engineering” or CREATE, is meant to remove certain limitations of CRISPR to allow for more wide-reaching research in the future.
Biopharma giant Abbvie has announced the acquisition of Allergan for $63 billion in cash and stock. Abbvie said the deal would be “transformational” for both companies, allowing Abbvie to diversify its business while focusing on scientific research and the company’s pipeline.
The amount of data captured by pharma companies today is fast outpacing best use for it. The ever-evolving scope of the field also means that many senior-level professionals do not fully understand the importance of getting data right in their business, or missing a potential opportunity that their rivals seize. Stemming from Front Line Genomics’ […]
University of Connecticut scientists have found that both severe epilepsy and breathing irregularities leading to sudden death are linked to the same gene mutation.
Consumer genomics company Ancestry has launched the new upgrade to its AncestryDNA experience, Ancestry Communities. Contrary to many commercial DNA sites, Communities promises to specify UK users’ genetic ancestry to a county level.